Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06381583 · ClinicalTrials.gov registry record
A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 658
- Enrollment target
NCT06381583 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 658 participants.
The verdict
NCT06381583 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 658 participants
- Enrollment target
Study Summary
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.
Interventions
- DIAGNOSTIC_TEST EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 658 participants |
| Start Date | 2023-04-15 |
| Est. Completion | 2024-04-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06381583
The ClinicalTrials.gov registry entry for NCT06381583 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 658 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia) is the first listed.
NCT06381583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06381583 about?
NCT06381583 is a clinical study titled "A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma". This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.
What is the current status of trial NCT06381583?
This trial is currently completed. The enrollment target is 658 participants. The study started on 2023-04-15. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT06381583?
The interventions under investigation include: EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06381583?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.